STE · Insider Trading
STERIS plc
Every open-market purchase and sale reported by STE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Karen L Burton | Sr. Vice Pres., CFO | F | −228 | — |
| 2026-08-12 | Christopher S Holland | Director | A | +1,025 deriv. | — |
| 2026-08-12 | Paul Edward Martin | Director | A | +2,018 deriv. | — |
| 2026-08-12 | Esther M. Alegria | Director | A | +2,018 deriv. | — |
| 2026-08-12 | Cynthia L Feldmann | Director | A | +2,018 deriv. | — |
| 2026-08-12 | Mohsen Sohi | Director | MIXED | — | −$606.87K |
| 2026-08-12 | Nirav R Shah | Director | A | +2,018 deriv. | — |
| 2026-08-12 | Pierre Boulud | Director | A | +1,025 deriv. | — |
| 2026-08-12 | Louis Shapiro | Director | A | +1,025 deriv. | — |
| 2026-07-02 | Mohsen Sohi | Director | MIXED | +1,944 | −$120.03K |
| 2026-06-16 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | Sell | −1,419 | −$296.97K |
| 2026-06-08 | Mary Clare Fraser | SVP & Chief HRO | F | −600 | −$127.34K |
| 2026-06-08 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | −401 | −$85.11K |
| 2026-06-08 | Renato Tamaro | V.P. & Corporate Treasurer | F | −65 | −$13.80K |
| 2026-06-08 | Kenneth E Kohler | SVP & GM, AST | F | −150 | −$31.84K |
| 2026-06-08 | Daniel A Carestio | President and CEO | MIXED | −6,317 | −$1.35M |
| 2026-06-08 | Julia Madsen | Sr. VP and GM, Life Sciences | F | −195 | −$41.39K |
| 2026-06-08 | Karen L Burton | Sr. Vice Pres., CFO | F | −90 | −$19.10K |
| 2026-06-05 | Karen L Burton | Sr. Vice Pres., CFO | F | −190 | −$39.94K |
| 2026-06-05 | Daniel A Carestio | President and CEO | F | −2,619 | −$550.49K |
| 2026-06-05 | Mary Clare Fraser | SVP & Chief HRO | F | −311 | −$65.37K |
| 2026-06-05 | Kenneth E Kohler | SVP & GM, AST | F | −184 | −$38.67K |
| 2026-06-05 | Julia Madsen | Sr. VP and GM, Life Sciences | F | −239 | −$50.24K |
| 2026-06-05 | Renato Tamaro | V.P. & Corporate Treasurer | F | −64 | −$13.45K |
| 2026-06-05 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | −365 | −$76.72K |
| 2026-06-04 | Richard C Breeden | Director | MIXED | +2,300 | −$40.32K |
| 2026-06-04 | Pierre Boulud | Director | A | +367 deriv. | — |
| 2026-06-04 | Karen L Burton | Sr. Vice Pres., CFO | MIXED | +5,259 | −$13.84K |
| 2026-06-04 | Daniel A Carestio | President and CEO | MIXED | +22,741 | −$208.71K |
| 2026-06-04 | Mary Clare Fraser | SVP & Chief HRO | MIXED | +2,418 | −$123.97K |
| 2026-06-04 | Kenneth E Kohler | SVP & GM, AST | MIXED | +2,133 | −$13.84K |
| 2026-06-04 | Julia Madsen | Sr. VP and GM, Life Sciences | MIXED | +2,189 | −$26.64K |
| 2026-06-04 | Cary L Majors | SVP and President, Healthcare | MIXED | +4,679 | −$14.05K |
| 2026-06-04 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | MIXED | +826 | −$69.01K |
| 2026-06-04 | Renato Tamaro | V.P. & Corporate Treasurer | MIXED | +709 | −$8.60K |
| 2026-06-04 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | MIXED | +4,112 | −$51.81K |
| 2026-06-03 | Karen L Burton | Sr. Vice Pres., CFO | F | −99 | — |
| 2026-06-03 | Daniel A Carestio | President and CEO | F | −1,254 | — |
| 2026-06-03 | Mary Clare Fraser | SVP & Chief HRO | F | −673 | — |
| 2026-06-03 | Kenneth E Kohler | SVP & GM, AST | F | −109 | — |
| 2026-06-03 | Julia Madsen | Sr. VP and GM, Life Sciences | F | −208 | — |
| 2026-06-03 | Cary L Majors | SVP and President, Healthcare | F | −768 | — |
| 2026-06-03 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | F | −198 | — |
| 2026-06-03 | Renato Tamaro | V.P. & Corporate Treasurer | F | −81 | — |
| 2026-06-03 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | −337 | — |
| 2026-03-06 | Cynthia L Feldmann | Director | MIXED | — | −$262.99K |
| 2026-01-06 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | A | +798 | — |
| 2025-11-25 | Julia Madsen | Sr. VP and GM, Life Sciences | MIXED | — | −$669.96K |
| 2025-11-20 | Renato Tamaro | V.P. & Corporate Treasurer | MIXED | −1,500 | −$652.71K |
| 2025-11-13 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | MIXED | — | −$2.93M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel A Carestio | President and CEO | 68,075 | $17.50M |
| Richard C Breeden | Director | 67,687 | $17.40M |
| Michael J Tokich | Sr. Vice Pres., CFO | 47,483 | $12.21M |
| John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | 35,259 | $9.07M |
| Mohsen Sohi | Director | 28,363 | $7.29M |
| Cary L Majors | SVP and President, Healthcare | 17,472 | $4.49M |
| Mary Clare Fraser | SVP & Chief HRO | 13,716 | $3.53M |
| Karen L Burton | Sr. Vice Pres., CFO | 12,956 | $3.33M |
| Cynthia L Feldmann | Director | 12,466 | $3.21M |
| Julia Madsen | Sr. VP and GM, Life Sciences | 12,257 | $3.15M |
| Kenneth E Kohler | SVP & GM, AST | 11,332 | $2.91M |
| Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | 6,240 | $1.60M |
| Renato Tamaro | V.P. & Corporate Treasurer | 6,194 | $1.59M |
| Christopher S Holland | Director | 1,055 | $271.26K |
| Nirav R Shah | Director | 292 | $75.08K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.